Could suboptimal magnesium and zinc increase inflammation and impair endocrine function?

Suboptimal levels of essential minerals like magnesium and zinc are increasingly recognized as primary drivers of systemic inflammation and endocrine disruption.

Clinical and mechanistic pathways of inflammation

• Inflammatory biomarkers: Suboptimal magnesium and zinc levels directly elevate systemic inflammatory biomarkers, specifically high-sensitivity C-reactive protein (hs-CRP), interleukin-6 (IL-6), and tumor necrosis factor-alpha (TNF-alpha).
• Cellular mechanisms: Mechanistically, magnesium acts as an inhibitor of nuclear factor-kappa B (NF-kB) activation; its deficiency triggers the transcription of pro-inflammatory cytokines. Zinc deficiency accelerates oxidative stress and inflammatory cytokine production, whereas clinical trials show that targeted supplementation of both minerals consistently reduces circulating CRP.

Endocrine and hormonal disruption

• Thyroid physiology: Both minerals are critical for thyroid axis homeostasis. Zinc is a required cofactor for the 5'-deiodinase enzyme that converts thyroxine (T4) to active triiodothyronine (T3) and is structurally vital for TRH, TSH, and thyroid receptors. Magnesium is similarly essential for thyroid hormone synthesis and T4-to-T3 conversion, with deficiency strongly linked to Hashimoto's thyroiditis.
• Testicular steroidogenesis: Within the testes, magnesium supports ATP-dependent mitochondrial steroidogenesis in Leydig cells, while zinc acts as a Leydig cell cofactor and supports luteinizing hormone (LH) secretion. Deficiencies in either mineral impair testosterone synthesis and bioavailability.
• Inflammatory crosstalk: This endocrine decline is compounded by systemic inflammation, as elevated hs-CRP and pro-inflammatory cytokines directly suppress Leydig cell steroidogenesis, HPG axis signaling, and thyroid hormone activation.

Bottom line

• Suboptimal magnesium and zinc status directly drive chronic low-grade inflammation and impair thyroid and testosterone production through overlapping mitochondrial, enzymatic, and inflammatory pathways. Correcting these micronutrient deficiencies is a clinically viable strategy to suppress systemic inflammation and restore optimal endocrine output.